Kobe Medical Industrial City Promotion Organization and Celide Therapeutics sign a joint research agreement to develop vascular regeneration products using in vitro expanded human hematopoietic stem cells
*View in browser* *Celeide Therapeutics Co., Ltd.*
Press release: March 28, 2024
**
Kobe Medical Industrial City Promotion Organization and Celide Therapeutics sign a joint research agreement to develop vascular regeneration products using in vitro expanded human hematopoietic stem cells
We would like to inform you that Kobe Medical Industrial City Promotion Organization (Public Interest Incorporated Foundation) (Chairman: Tasuku Honjo) and Cereide Therapeutics Co., Ltd.
(Headquarters: Bunkyo-ku, Tokyo, Representative Director: Nobuyuki Arakawa) have entered into a joint research agreement. Masu. This research is based on the mechanism of angiogenesis by
hematopoietic stem cells providing an energy source via gap junctions (intercellular tunnels formed by Connexin molecules), which was discovered by the research team led by Akihiko Taguchi, director of the Brain Circulation and Metabolism Research Department, Advanced Medical Research Center. , regarding the angiogenic function of in vitro amplified human hematopoietic stem cells from Ceride
Therapeutics *
in vitro * and * in vivo*
We will perform functional verification using (animal experiments). Through this research, we will advance research and development into vascular regeneration treatment using human hematopoietic stem cells based on domestically produced technology and research results, and provide a solution for patients suffering from ischemic diseases (cerebro/myocardial infarction, childhood cerebral palsy, ischemic lower limbs, etc.). We will continue to work hard to deliver therapeutic drugs as soon as possible.
Kobe Medical Industry City Promotion Organization Overview
The Kobe Medical Industrial City Promotion Organization was
established in March 2000 as a foundation that serves as the core support organization for the creative reconstruction project “Kobe Medical Industrial City” following the Great Hanshin-Awaji
Earthquake, as well as advanced medical research functions. In April 2018, the organization was reorganized into the Kobe Medical Industry City Promotion Organization, and we are promoting our business with the goal of “disseminating solutions to problems for a healthy and long-lived society from Kobe to the world.”
* *The FBRI logo is a registered trademark of the Kobe Medical Industry City Promotion Organization. *
Ceride Therapeutics Overview
Ceraid Therapeutics is a startup from the University of Tokyo and the University of Tsukuba that has unique technology to selectively amplify hematopoietic stem cells, which are the source of human blood, in vitro. By safely and efficiently increasing hematopoietic stem cells, we can provide cell therapy for intractable blood diseases and genetic diseases, including blood cancers.*
We aim to provide society with next-generation regenerative medicine products for ex vivo * hematopoietic stem cell gene therapy and angiogenesis in ischemic diseases.
* -Contact information regarding this matter-*
*Kobe Medical Industry City Promotion Organization*
Corporate Planning Department IBRI Business Promotion Division Hayashi TEL: 078-306-0708 FAX: 078-306-1708
E-mail: kenkyu-fbri (please add @fbri.org at the end)
*Celeide Therapeutics Co., Ltd.*
Head office location: Entrepreneur Lab, South Research Building, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo
TEL: 050-3612-7767／E-mail: contact@celaidtx.com
URL: https://celaidtx.com/
*About details about this release*
https://prtimes.jp/main/html/rd/p/000000008.000100408.html